New insights regarding HCV-NS5A structure/function and indication of genotypic differences.

Background: HCV is prevalent throughout the world. It is a major cause of chronic liver disease. There is no effective vaccine and the most common therapy, based on Peginterferon, has a success rate of ~50%.